Q BioMed Inc (QBIO)

[ProfitScout]

This is especially important news from QBIO today as it serves both to make a significant contribution towards helping many patients worldwide who need the valuable therapeutic value of Strontium89 and additionally, new revenues to the company from this program should be considerable and begin almost immediately.

From the news:

In September, Q BioMed launched its international 'Named Patient' program that enables physicians worldwide to order Strontium89 for their patients in need, and the response to this program has been robust with orders already taken in the UK and orders pending from at least 7 other countries. The regulatory registration process for full commercial access in the EU has commenced, with pan-EU approval expected by end of year. In parallel, Q BioMed is midway through the registration process in many other countries, with approvals expected to begin in October and continue through Q1 of 2021.

"We anticipate revenues from Strontium89 to continue to ramp up significantly from our baseline in Q2 as we build capacity and demand worldwide. Looking towards 2021, we are assessing several potential clinical trial programs that may expand the indication beyond palliation into a therapeutic use that may increase patient survival, accessing the much larger therapeutic market," stated Q BioMed CEO Denis Corin.